147 related articles for article (PubMed ID: 9811521)
1. Inactivation of viruses by beta-propiolactone in human cryo poor plasma and IgG concentrates.
Scheidler A; Rokos K; Reuter T; Ebermann R; Pauli G
Biologicals; 1998 Jun; 26(2):135-44. PubMed ID: 9811521
[TBL] [Abstract][Full Text] [Related]
2. Validation of virus inactivation and removal for the manufacturing procedure of two immunoglobulins and a 5% serum protein solution treated with beta-propiolactone.
Dichtelmüller H; Rudnick D; Breuer B; Gänshirt KH
Biologicals; 1993 Sep; 21(3):259-68. PubMed ID: 8117439
[TBL] [Abstract][Full Text] [Related]
3. The effect of chemical inactivation of bovine viral diarrhea virus with beta-propiolactone and binary ethyleneimine on plasma proteins and coagulation factors.
Refaie FM; Esmat AY; Mohamed AF; Mohamed WA
Egypt J Immunol; 2004; 11(2):9-20. PubMed ID: 16734113
[TBL] [Abstract][Full Text] [Related]
4. A rapid method for the inactivation of virus infectivity prior to assay for interferons.
Barrett AD; Hunt N; Dimmock NJ
J Virol Methods; 1984 Jul; 8(4):349-51. PubMed ID: 6206084
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of beta-propiolactone on mice, mouse-derived cell cultures, and Venezuelan equine encephalomyelitis virus.
HEARN HJ; DAWSON FW
Appl Microbiol; 1961 Jul; 9(4):278-82. PubMed ID: 13712596
[TBL] [Abstract][Full Text] [Related]
6. Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat.
Borovec S; Broumis C; Adcock W; Fang R; Uren E
Biologicals; 1998 Sep; 26(3):237-44. PubMed ID: 10208725
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of inactivation of enveloped viruses by the biosurfactant surfactin from Bacillus subtilis.
Vollenbroich D; Ozel M; Vater J; Kamp RM; Pauli G
Biologicals; 1997 Sep; 25(3):289-97. PubMed ID: 9324997
[TBL] [Abstract][Full Text] [Related]
8. Beta-Propiolactone Inactivation of Coxsackievirus A16 Induces Structural Alteration and Surface Modification of Viral Capsids.
Fan C; Ye X; Ku Z; Kong L; Liu Q; Xu C; Cong Y; Huang Z
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148783
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of different inactivation methods for high and low pathogenic avian influenza viruses in egg-fluids for antigen preparation.
Pawar SD; Murtadak VB; Kale SD; Shinde PV; Parkhi SS
J Virol Methods; 2015 Sep; 222():28-33. PubMed ID: 25997377
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the beta-propiolactone sensitivity and optimization of inactivation methods for human influenza H3N2 virus.
Sasaki Y; Yoshino N; Sato S; Muraki Y
J Virol Methods; 2016 Sep; 235():105-111. PubMed ID: 27142111
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of hepatitis viruses and HIV in plasma and plasma derivatives by treatment with beta-propiolactone/UV irradiation.
Stephan W
Curr Stud Hematol Blood Transfus; 1989; (56):122-7. PubMed ID: 2642784
[TBL] [Abstract][Full Text] [Related]
12. Validation of betapropiolactone (BPL) as an inactivant for infectious bovine rhinotracheitis (IBR) virus.
Kamaraj G; Lakshmi Narasu M; Srinivasan VA
Res Vet Sci; 2008 Dec; 85(3):589-94. PubMed ID: 18262212
[TBL] [Abstract][Full Text] [Related]
13. Viral safety of APOSECTM: a novel peripheral blood mononuclear cell derived-biological for regenerative medicine.
Gugerell A; Sorgenfrey D; Laggner M; Raimann J; Peterbauer A; Bormann D; Suessner S; Gabriel C; Moser B; Ostler T; Mildner M; Ankersmit HJ
Blood Transfus; 2020 Jan; 18(1):30-39. PubMed ID: 30865581
[TBL] [Abstract][Full Text] [Related]
14. beta-Propiolactone: viral inactivation in vaccines and plasma products.
Lawrence SA
PDA J Pharm Sci Technol; 2000; 54(3):209-17. PubMed ID: 10927912
[No Abstract] [Full Text] [Related]
15. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of viruses in blood and plasma products.
Suomela H
Transfus Med Rev; 1993 Jan; 7(1):42-57. PubMed ID: 8431658
[No Abstract] [Full Text] [Related]
17. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
Troccoli NM; McIver J; Losikoff A; Poiley J
Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
[TBL] [Abstract][Full Text] [Related]
19. Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process.
Bos OJ; Sunyé DG; Nieuweboer CE; van Engelenburg FA; Schuitemaker H; Over J
Biologicals; 1998 Dec; 26(4):267-76. PubMed ID: 10403030
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light.
Lin L; Hanson CV; Alter HJ; Jauvin V; Bernard KA; Murthy KK; Metzel P; Corash L
Transfusion; 2005 Apr; 45(4):580-90. PubMed ID: 15819680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
